Hugo M. Oliveira

Prof. Hugo M. Oliveira

Faculty of Medicine of University of Porto, Porto, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2016 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
CPC.M. Pereira
C.M. Pereira
Hugo M. OliveiraHugo M. Oliveira
Hugo M. Oliveira
VLV. Lopes
V. Lopes
JGJ. Gandara
J. Gandara
SFS. Ferreira
S. Ferreira
HMH.P. Miranda
H.P. Miranda

6 June 2024 in Annals of Hepatology
Verified
Journal Article
Open access
Hugo M. OliveiraHugo M. Oliveira
Hugo M. Oliveira
HMHelena Pessegueiro Miranda
Helena Pessegueiro Miranda
Francisca RegoFrancisca Rego
Francisca Rego
Rui NunesRui Nunes
Rui Nunes
Introduction and Objectives Prevalence and mortality of chronic liver disease have risen significantly. In end stage liver disease, the survival of patients is approximately two years. Despite the poor prognosis and high symptom burden of these patients, integration of palliative care is limited. We aim to assess associated factors and trends in palliative care use in recent years. Materials and Methods A Multicenter retrospective cohort of patients with end stage liver disease who suffered in-hospital mortality between 2017 and 2019. Information regarding patient demographics, hospital characteristics, comorbidities, etiology, decompensations, and interventions was collected. Two-sided tests and logistic regression analysis were used to identify factors associated with palliative care use. Results: A total of 201 patients were analyzed, with a yearly increase in palliative care consultation: 26.7 % in 2017 to 38.3 % in 2019. Patients in palliative care were older (65.72 ± 11.70 vs. 62.10 ± 11.44; p = 0.003), had a lower Karnofsky functionality scale (χ=18.104; p = 0.000) and had higher rates of hepatic encephalopathy (32.1 % vs. 17.4 %, p = 0.007) and hepatocarcinoma (61.7 % vs. 26.2 %; p = 0.000). No differences were found for Model for End-stage Liver Disease (19.28 ± 6.60 vs. 19,90 ± 5.78; p = 0.507) or Child-Pugh scores (p = 0.739). None of the patients who die in the intensive care unit receive palliative care (0 % vs 31.6 %; p = 0.000). Half of the palliative care consultations occurred 6,5 days before death. Conclusions: Palliative care use differs based on demographics, disease complications, and severity. Despite its increasing implementation, palliative care intervention occurs late. Future investigations should identify approaches to achieve an earlier and concurrent care model.

1 February 2016 in Digestive and Liver Disease
Verified
Journal Article
Closed access
PDF file
Hugo M. OliveiraHugo M. Oliveira
Hugo M. Oliveira
CPCláudia Pereira
Cláudia Pereira
ESErmelinda Santos Silva
Ermelinda Santos Silva
JPJorge Pinto-Basto
Jorge Pinto-Basto
HMHelena Pessegueiro Miranda
Helena Pessegueiro Miranda

8 July 2024 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Open access
Hugo M. OliveiraHugo M. Oliveira
Hugo M. Oliveira
JRJosé Presa Ramos
José Presa Ramos
Francisca RegoFrancisca Rego
Francisca Rego
Rui NunesRui Nunes
Rui Nunes
Background and aims The prevalence and mortality of chronic liver disease has risen significantly. In end stage liver disease (ESLD) the survival of patients is approximately 2 years. Despite the poor prognosis and high symptom burden of these patients, integration of palliative care is reduced. We aim to analyze the agreement between palliative care and hepatology physicians of clinical scenarios that could require palliative care intervention. Methods: A cross-sectional study was conducted. Palliative care and hepatology physicians were surveyed. Using a five-point Likert scale, their perceptions of palliative care in ESLD were rated. Their agreement in clinical scenarios that could require palliative care intervention were evaluated. Analyses were conducted to assess any differences by primary role (hepatology vs. palliative care) and length of practice (<10 years vs. 10 years). Results: A total of 123 responses were obtained: 52% from palliative care and 48% from hepatology. The majority (66.7%) work in the field for up to ten years. There was a great consensus in 4 of the 8 clinical scenarios. In scenarios with less consensus, the area of activity and length of practice influence the reliance of physicians on palliative care. Involvement of palliative care in ESLD was considered “rare” by 30% and 61% consider difficult to predict the prognosis. More than 90% support medical training in both areas of activity. Conclusion: The current involvement of palliative care is considered low, but there are clinical conditions that reveal a clear consensus and there's a unanimous view of the relevance of training.

14 November 2024 in Journal of Palliative Care
Verified
Journal Article
Open access
Hugo M. OliveiraHugo M. Oliveira
Hugo M. Oliveira
CRCéu Rocha
Céu Rocha
MRMaria Francisca Rego
Maria Francisca Rego
RNRui Nunes
Rui Nunes
Objective: The prevalence and mortality of chronic liver disease has risen significantly. In end-stage liver disease (ESLD), the survival of patients is approximately 2 years. Despite the poor prognosis and high symptom burden, integration of palliative care in ESLD is reduced, and the majority of patients continue to die in inpatient care. We aim to assess predictors and outcomes of home palliative care, as well as factors associated with death at home in patients with ESLD. Methods: Retrospective cohort study of patients with ESLD, followed by a palliative care team between 2017 and 2022. Information regarding patient demographics, ESLD etiology, decompensations, and interventions was collected. Two-sided tests were used to identify factors associated with home palliative care. Results: We analyzed 75 patients: 44% had home palliative care and 33% died at home. ESLD patients with home palliative care were older (72.52 vs 64.45; p = 0.002), had a longer palliative care intervention time (149.97 ± 196.23 vs 43.69 ± 100.60 days; p = 0.007), higher rates of ascites or hepatic encephalopathy (χ 2 = 11.024; p = 0.029), and hepatocarcinoma (90.9% vs 64.3%; p = 0.007). Patients with home palliative care had a reduction in-hospital admissions (2.61 vs 1.06; p = 0.000) and a greater probability of death at home (66.7% vs 33.3%; p = 0.000). Patients who died at home (33.3%) were older (72.20 vs 64.40; p = 0.000) and had longer palliative care intervention time (178.80 ± 211.78 vs 46.28 ± 99.67 days; p = 0.006). Conclusion: Home palliative care in ESLD differs based on demographics and disease complications, with a positive impact of homecare translated into a reduction in hospital admissions and an increased probability of death at home.

27 March 2017 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
Hugo M. OliveiraHugo M. Oliveira
Hugo M. Oliveira
CPClaudia Pereira
Claudia Pereira
ESErmelinda Santos Silva
Ermelinda Santos Silva
JPJorge Pinto-Basto
Jorge Pinto-Basto
JVJosé R Vizcaíno
José R Vizcaíno
HPHelena Pessegueiro-Miranda
Helena Pessegueiro-Miranda
A New Mutation Causing Progressive Familiar Intrahepatic Cholestasis Type 3 in Association with Autoimmune Hepatitis